Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases

Journal of Urology

Volumn 182, Issue 4 SUPPL., 2009, Pages 1860-1868

  Fitzgerald, John P ^a,b   Chou, Shyan Yih ^a,b   Franco, Israel ^a,b   Mooppan, Unni M ^a,b   Kim, Hong ^a,b   Saini, Rajiv ^a,b   Gulmi, Frederick A ^a,b  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Atorvastatin; Fibrosis; Kidney; Nephrectomy; Ureteral obstruction

Indexed keywords

ATORVASTATIN; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ANIMAL; ARTICLE; CHRONIC DISEASE; DRUG EFFECT; FIBROSIS; KIDNEY; KIDNEY TUBULE; MALE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; URETER OBSTRUCTION;

ANIMALS; CHRONIC DISEASE; FIBROSIS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; KIDNEY TUBULES; MALE; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; URETERAL OBSTRUCTION;

EID: 70350506552     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2009.04.086     Document Type: Conference Paper

References (24)

1. Klahr S and Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283: F861.
2. Gobet R, Cisek L, Chang B et al: Experimental fetal vesicoureteral reflux induces renal tubular and glomerular damage and is associated with persistent bladder instability. J Urol 1999; 162: 1090.
3. Chevalier RL: Molecular and cellular pathophysiology of obstructive nephropathy. Pediatr Nephrol 1999; 13: 612.
4. Bascands JL and Schanstra JP: Obstructive nephropathy: insights from genetically engineered animals. Kidney Int 2005; 68: 925.
5. Guo G, Morrissey J and McCracken R: Contributions of angiotensin II and tumor necrosis factoralpha to the development of renal fibrosis. Am J Physiol Renal Physiol 2001; 280: F777.
6. Klahr S, Ishidoya S and Morrissey J: Role of angiotensin II in the tubulointerstitial fibrosis of obstructive nephropathy. Am J Kidney Dis 1995; 26: 141.
7. Elisaf M and Mikhailidis DP: Statins and renal function. Angiology 2002; 53: 493.
8. McKenney JM: Potential nontraditional applications of statins. Ann Pharmacother 2003; 37: 1063.
9. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110: 285.
10. Huang A, Palmer L, Hom D et al: Ibuprofen combined with antibiotics suppresses renal scarring due to ascending pyelonephritis in rats. J Urol 1999; 162: 1396.
11. Bennett RT, Mazzaccaro NC, Melman A et al: Suppression of renal inflammation with vitamins A and E in ascending pyelonephritis in rats. J Urol 1999; 161: 1681.
12. Mizuguchi Y, Miyajima A and Kosaka T: Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. J Urol 2004; 172: 2456.
13. Moriyama T, Kawada N and Nagatoya K: Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001; 59: 2095.
14. Guo G, Morrissey J and McCracken R: Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol 1999; 277: F766.
15. Ulm AH and Miller F: An operation to produce experimental reversible hydronephrosis in dogs. J Urol 1962; 88: 337.
16. Vaughan ED Jr, Marion D and Poppas DP: Pathophysiology of unilateral ureteral obstruction: studies from Charlottesville to New York. J Urol 2004; 172: 2563.
17. Debelle FD, Nortier J, De Prez E et al: Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 2002; 13: 431.
18. Fern RJ, Yesko CM and Thornhill BA: Reduced angiotensinogen expression attenuates renal interstitial fibrosis in obstructive nephropathy in mice. J Clin Invest 1999; 103: 39.
19. Klahr S and Morrissey JJ: The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 1998; 18: 622.
20. Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature 1990; 343: 425.
21. Takemoto M and Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712.
22. Vaughan CJ, Murphy MB and Buckley BM: Statins do more than just lower cholesterol. Lancet 1996; 348: 1079.
23. Krause BR and Newton RS: Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 1995; 117: 237.
24. Nath KA: Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1.